Ian Sheffield Acquires 35,000 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ian Sheffield bought 35,000 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director directly owned 35,000 shares in the company, valued at approximately $25,550. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Fractyl Health Price Performance

NASDAQ:GUTS opened at $0.85 on Friday. Fractyl Health, Inc. has a 52 week low of $0.38 and a 52 week high of $2.45. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $134.85 million, a PE ratio of -0.66 and a beta of 2.34. The stock’s 50-day moving average price is $0.69 and its 200-day moving average price is $1.07.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities analysts expect that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently bought and sold shares of the company. Rosalind Advisors Inc. purchased a new stake in shares of Fractyl Health in the third quarter valued at approximately $7,950,000. JPMorgan Chase & Co. purchased a new position in Fractyl Health during the third quarter worth approximately $81,000. Centiva Capital LP purchased a new position in Fractyl Health during the third quarter worth approximately $78,000. Prelude Capital Management LLC purchased a new position in Fractyl Health during the third quarter worth approximately $55,000. Finally, Scientech Research LLC purchased a new position in Fractyl Health during the third quarter worth approximately $49,000.

Wall Street Analysts Forecast Growth

GUTS has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.